1.Effect of transcatheter arterial chemoembolization combined with interferon adjuvant therapy in treatment of ad-vanced primary liver cancer:a meta-analysis
Journal of Clinical Hepatology 2016;32(1):76-79
Objective Toinvestigatetheeffectoftranscatheterarterialchemoembolization(TACE)combinedwithinterferon(IFN)adju-vanttherapyinthetreatmentofadvancedprimarylivercancer,andtoprovidenewideasforadjuvanttherapiesafterTACE.Methods The databases including Cochrane Library,PubMed,Medline,Embase,CNKI,Wanfang Data,and VIP were searched to obtain all articles pub-lished before January 2015,and the randomized controlled trials (RCTs)about the comparison between TACE combined with IFN and TACE alone published in journals at home and abroad were included.Quality assessment and data extraction were performed for these articles,and Revman5.1softwarewasappliedforthemeta-analysis.Results Atotalof6RCTswereincluded,consistingof311patientsintheIFN adjuvant therapy group and 308 patients in the placebo group.The results of the meta -analysis showed that compared with the placebo group,the IFN adjuvant treatment group had significantly lower 1 -,2-,and 3-year recurrence rates and a significantly higher 1 -year survivalrate(P=0.006,0.002,0.002,and0.030).Conclusion IFNadjuvanttherapycanreducetheriskoflivercancerrecurrence after TACE and improve the patients′survival rate.
2.Prevalence and prognostic impact of hepatopulmonary syndrome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective cohort study.
He ZHAO ; Jiaywei TSAUO ; Xiaowu ZHANG ; Huaiyuan MA ; Ningna WENG ; Zhengqiang YANG ; Xiao LI
Chinese Medical Journal 2022;135(17):2043-2048
BACKGROUND:
To determine the prevalence and prognostic impact of hepatopulmonary syndrome (HPS) in patients with unresectable hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).
METHODS:
Fifty-four patients with unresectable HCC undergoing TACE between December 2014 and December 2015 were prospectively screened for HPS and were followed up for a maximum of 2 years or until the end of this prospective study.
RESULTS:
Nineteen of the 54 (35.2%) patients were considered to have HPS, including one (5.3%) with severe HPS, nine (47.4%) with moderate HPS, and nine (47.4%) with mild HPS. The median overall survival (OS) was 10.1 (95% confidence interval [CI], 3.9-16.3) months for patients with HPS and 15.1 (95% CI, 7.3-22.9) months for patients without HPS, which is not a significant difference ( P = 0.100). The median progression-free survival was also not significantly different between patients with and without HPS (5.2 [95% CI, 0-12.8] vs. 8.4 [95% CI, 3.6-13.1] months; P = 0.537). In the multivariable Cox regression analyses, carbon monoxide diffusing capacity (hazard ratio [HR] = 1.033 [95% CI, 1.003-1.064]; P = 0.028) and Child-Pugh class (HR = 1.815 [95% CI, 1.011-3.260]; P = 0.046) were identified to be the independent prognostic factors of OS.
CONCLUSION
Mild or moderate HPS is common in patients with unresectable HCC undergoing TACE, but it does not seem to have a significant prognostic impact.
Humans
;
Carcinoma, Hepatocellular/pathology*
;
Chemoembolization, Therapeutic
;
Prospective Studies
;
Liver Neoplasms/pathology*
;
Prognosis
;
Hepatopulmonary Syndrome/therapy*
;
Prevalence
;
Treatment Outcome
;
Retrospective Studies
3.Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma.
Ningna WENG ; Siyuan QIN ; Jiayang LIU ; Xing HUANG ; Jingwen JIANG ; Li ZHOU ; Zhe ZHANG ; Na XIE ; Kui WANG ; Ping JIN ; Maochao LUO ; Liyuan PENG ; Edouard C NICE ; Ajay GOEL ; Suxia HAN ; Canhua HUANG ; Qing ZHU
Acta Pharmaceutica Sinica B 2022;12(7):3085-3102
Pancreatic ductal adenocarcinoma (PDAC) is characterized by the highest mortality among carcinomas. The pathogenesis of PDAC requires elevated autophagy, inhibition of which using hydroxychloroquine has shown promise. However, current realization is impeded by its suboptimal use and unpredictable toxicity. Attempts to identify novel autophagy-modulating agents from already approved drugs offer a rapid and accessible approach. Here, using a patient-derived organoid model, we performed a comparative analysis of therapeutic responses among various antimalarial/fungal/parasitic/viral agents, through which econazole (ECON), an antifungal compound, emerged as the top candidate. Further testing in cell-line and xenograft models of PDAC validated this activity, which occurred as a direct consequence of dysfunctional autophagy. More specifically, ECON boosted autophagy initiation but blocked lysosome biogenesis. RNA sequencing analysis revealed that this autophagic induction was largely attributed to the altered expression of activation transcription factor 3 (ATF3). Increased nuclear import of ATF3 and its transcriptional repression of inhibitor of differentiation-1 (ID-1) led to inactivation of the AKT/mammalian target of rapamycin (mTOR) pathway, thus giving rise to autophagosome accumulation in PDAC cells. The magnitude of the increase in autophagosomes was sufficient to elicit ER stress-mediated apoptosis. Furthermore, ECON, as an autophagy inhibitor, exhibited synergistic effects with trametinib on PDAC. This study provides direct preclinical and experimental evidence for the therapeutic efficacy of ECON in PDAC treatment and reveals a mechanism whereby ECON inhibits PDAC growth.